Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

ically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's ability to advance its clinical and preclinical pipeline, including completing its ongoing Phase 3 clinical trials of OMS103HP and funding the commercial launch of OMS103HP with the proceeds from its initial public offering; to realize the value of its GPCR program while limiting the Company's expenditures as a result of changes to its agreement with Patobios Limited; to release data from its Phase 3 arthroscopic program as well as meet additional clinical milestones for its ophthalmologic and urologic programs over the course of next year; and to de-orphanize orphan GPCRs and grant related development and/or commercialization rights to third parties. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors des
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Cereal grain scientists, quality regulators, ... October 5–8, 2014, for the AACC International (AACCI) ... in Providence, Rhode Island. The comprehensive scientific program ... scientists, chemists, microbiologists, nutritionists, and those interested in ... To date, 1,000 attendees have registered for the ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
Breaking Biology Technology:Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3
... Jan. 28 Ther-Rx Corporation, a,subsidiary of KV ... KV Pharmaceutical Company on January 26, 2009, a ... lots within,expiration) as a precautionary measure because they ... sufficiently comply with current Good,Manufacturing Practices (cGMPs). , ...
... Product is Japan,s first second-generation drug-eluting stentNATICK, Mass., ... BSX ) announced today that it has ... Labor and Welfare (MHLW) to market its TAXUS(R) ... plans to launch the product as soon as ...
... NOVATO, Calif., Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: ... BioMarin, will host a conference call and webcast on,Wednesday, February ... quarter,and full year 2008 financial results. , , ... International Dial-in Number: 617.213.8835, Participant ...
Cached Biology Technology:Ther-Rx Corporation Issues Nationwide Voluntary Recall of Products 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 2Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2
(Date:9/19/2014)... Oklahoma biology professor will study the unique bioelectric signaling ... eventually benefit people,s health. The OU researcher is ... required to produce the signals used to map the ... at a rate of 500-600 discharges a second throughout ... electric fish are extreme, but necessary for survival. , ...
(Date:9/19/2014)... of fairness did not evolve for the sake of ... benefits of continued cooperation, so say Frans de Waal, ... article about inequity aversion (IA), which is defined as ... published in Science . , Their conclusion ... studies to address their hypothesis that it is the ...
(Date:9/19/2014)... 2014 Nxt-ID, Inc. (Nasdaq: NXTD and ... the growing m-commerce market, updates the "Wocket in Your Pocket" celebrity ... and light middleweight weight classes, Vinny Pazienza (PAZ). ... Game of Thrones actor Ciaran Hinds and ... star Katey Sagal have been cast in Bleed ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3
... them get psyched up for contests, but when these ... gobble down before and during events, they could be ... treatments for the symptoms of an injury, not the ... University focuses on musculoskeletal health and sports medicine. "They ...
... A University of Maryland School of Medicine researcher will ... nation,s most prominent scientists in the field of stem ... and Preventive Medicine, was chosen by the National Heart, ... of this consortium of national experts, which will be ...
... , , ... Dec. 2 Communication Intelligence Corporation ("CIC") (OTC Bulletin ... for business process automation in the financial industry* and ... Systems Inc. ("Docubase"), a leading International Electronic Document Management ...
Cached Biology News:NSAIDs: Take 'em early and often when competing? Think again 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4
... These skirted micro test tubes are ... of polypropylene, these tubes have uniform walls ... nonsterile, with separate O-ring screw caps. The ... and have an operating range from -55 ...
Caspr2 Antigen: Fusion protein amino acids 96-1265 (extracellular domain) of human Caspr2 Accession Number: NP_054860...
... to introduce its new line of Protein ... proteins for use in mass spectrometry, molecular ... Protein Standards are high quality purified proteins ... analyses by electrospray ionization mass spectrometry (ESI-MS). ...
Determin interaction of your protein with Echelons lipids...
Biology Products: